Piper Jaffray downgrades NxStage Medical (Nasdaq: NXTM) from Buy to Neutral and lowers its price target from $16 to $9.
This article: 108 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE